<DOC>
	<DOCNO>NCT01641341</DOCNO>
	<brief_summary>Overview Methods : This double blind , randomize controlled trial non-balanced randomization cross-over active treatment placebo treat individual respond placebo treatment . Data collect help determine feasibility study design primary care office . Patient outcome data provide precise estimate power large , classic randomize trial determine study reasonably undertaken within primary care practice . Aims : The aim pilot study : 1 ) Evaluate well Genova Diagnostics ( GDx ) IBS test integrate primary care , 2 ) examine effect Genova Diagnostics ( GDx ) test treatment , 3 ) observe track patient ' health , quality life clinical outcome relate IBS study period .</brief_summary>
	<brief_title>Irritable Bowel Syndrome Evaluation Treatment Primary Care</brief_title>
	<detailed_description>This study take place 8 practice member AAFP NRN . Eligible practice must able identify least 25 active patient ( see last 24 month ) diagnosis IBS bill electronic health record data eligible participate . Each practice ask recruit 10 patient . Adult patient identify physician IBS symptom term `` potentially eligible patient '' invite study via personal invitation present practice regularly-scheduled visit , letter mail patient practice letterhead sign physician , phone contact member practice . If patient agrees participate study , s/he ask read sign initial informed consent . Consent form include letter mail patient , additional copy consent keep practice . The initial informed consent cover consent stool testing , collection study outcome data include new diagnosis uncovered stool test follow procedure conduct result stool test result . This initial consent indicate base stool test result patient may refer evaluation open label treatment physician may recommend one study direct treatment ( ) . Once stool test return patient contact review result . At time patient ask sign secondary consent form study direct therapy recommend . This consent form consent form ( one therapy recommend ) treatment specific explain patient randomize active placebo treatment double blinded fashion , patient cross either active treatment placebo 8 week patient offer active treatment end study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>age 18 65 year age meet Rome III criterion IBS willing complete survey daily symptom log three four 14day period positive symptom least 3 day 14 day baseline daily log record HIV AIDs gall stone gall bladder present</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Genova Diagnostics kit</keyword>
	<keyword>Stool test</keyword>
	<keyword>Rome III</keyword>
	<keyword>Practice-based research</keyword>
	<keyword>treatable parasite</keyword>
	<keyword>Pancreatic insufficiency</keyword>
	<keyword>Bowel dysbiosis</keyword>
	<keyword>High level inflammation , C. difficile , H. pylorus</keyword>
</DOC>